Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 68, Issue 6, Pages 999-1009Publisher
SPRINGER
DOI: 10.1007/s00262-019-02342-8
Keywords
Meningioma; Immune checkpoint inhibition; Immunotherapy; PD-L1; Programmed death-ligand 1
Categories
Funding
- Howard Hughes Medical Institute Medical Student Research Fellows program
- NIH/NCI (National Cancer Institute) R01 [CA164714]
- NIH/National Institute of Neurological Disorders and Stroke (NINDS) R00 [NS078055]
- National Cancer Institute [CA206413]
- National Institute of Neurological Disorders and Stroke [NS101884]
Ask authors/readers for more resources
AimDespite current treatments, high-grade meningiomas continue to have a poor prognosis. Immunotherapy targeting immune checkpoints, such as PD-L1, has demonstrated significant success in controlling numerous malignancies. In this study, we investigate the extent of systemic and local immunosuppression in meningiomas to assess the potential benefit of immune checkpoint inhibitors for the treatment of high-grade meningiomas.MethodsPeripheral blood was collected from patients undergoing resection of meningiomas (WHO grade I, n=18; grade II, n=25; grade III, n=10). Immunosuppressive myeloid cells (CD45(+)CD11b(+)PD-L1(+)), myeloid-derived suppressor cells (MDSCs) (CD11b(+)CD33(+)HLA-DRlow), and regulatory T cells (Tregs) (CD3(+)CD4(+)CD25(+)FoxP3(+)) were quantified through flow cytometry. Tissue sections from the same patients were assessed for PD-L1 expression and T cell infiltration via immunohistochemistry.ResultsPatients with grade III meningiomas demonstrated increased peripheral monocyte PD-L1 compared to patients with grade I/II meningiomas and healthy controls. Peripheral MDSC abundance was increased in grades II and III meningioma patients. PD-L1 staining of meningioma tissue demonstrated increased positivity in grade III meningiomas. Intratumoral PD-L1 was not associated with progression-free survival. High-grade meningiomas had increased T-cell infiltration. However, a significant proportion of these T cells were exhausted PD1(+) T cells and immunosuppressive Tregs.ConclusionsPatients with meningiomas exhibit signs of peripheral immunosuppression, including increased PD-L1 on myeloid cells and elevated MDSC abundance proportional to tumor grade. Additionally, the tumors express substantial PD-L1 proportional to tumor grade. These results suggest a role for immune checkpoint inhibitors targeting the PD-L1/PD-1 pathway in combination with standard therapies for the treatment of high-grade meningiomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available